Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Compiled:THE U.S. FDA: 07/17/19

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 325
Posts 42,744
Boards Moderated 29
Alias Born 09/20/01
160x600 placeholder
Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B) GlobeNewswire Inc. - 5/21/2020 7:00:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2020 4:41:44 PM
Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business Updates GlobeNewswire Inc. - 5/7/2020 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020 GlobeNewswire Inc. - 5/5/2020 7:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/1/2020 7:08:41 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/1/2020 7:08:14 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/1/2020 7:03:26 AM
Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimer’s Disease GlobeNewswire Inc. - 4/23/2020 7:00:10 AM
Cannabis? CBD? That's Old News, A New Sector Bull Run Has Begun InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/8/2020 4:30:55 PM
Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19 GlobeNewswire Inc. - 3/31/2020 7:00:10 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 3/23/2020 8:01:22 AM
Anavex Life Sciences to Webcast 2020 Annual Meeting of Shareholders GlobeNewswire Inc. - 3/23/2020 8:00:10 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 3/9/2020 4:28:38 PM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS) GlobeNewswire Inc. - 2/24/2020 7:00:10 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/20/2020 4:32:14 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:38:56 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
PURA BUY Recommendation at $0.03 Issued By AmericanBulls InvestorsHub NewsWire - 2/7/2020 10:33:33 AM
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates GlobeNewswire Inc. - 2/6/2020 7:00:10 AM
Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference GlobeNewswire Inc. - 2/4/2020 7:00:10 AM
Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Developmen... GlobeNewswire Inc. - 2/3/2020 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020 GlobeNewswire Inc. - 1/30/2020 7:00:10 AM
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Dis... GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
XenaLives Member Level  Wednesday, 07/17/19 01:35:20 AM
Re: None
Post # of 252506 
Compiled:THE U.S. FDA: 07/17/19
_______________________________________________________________________________________________________

Janet Woodcock, FDA, on future innovation in drug development
https://youtu.be/vcPMzHntlzY
Comments on the above
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149424734

Gottleib - former FDA commissioner on CNBC on what he believes is an area of HUGE potential.
Start listening at 4:00 minute mark (from Lima4918)
https://www.cnbc.com/video/2019/06/17/fmr-fda-commissioner-on-biotech-cannabis-and-the-meatless-markets.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard

Coming change in FDA process - the office of innovation (Office of Drug Evaluation Science) 1/8/19:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145956816
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145966349

Will Fadiran negotiate a SPA with the FDA?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149960752

FDA leaks, a time honored tradition:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140883830

On what planet does the FDA put the health of the people first?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140058548

The FDA, pay for play, and peer review:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141334023

3/14/19 Update from Gottlieb on changes in drug trial procedure
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147558978

New(Feb 2019) guidance highlights basis for possible early approval of 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146543702

This could speed up and simplify and reduce cost of “precision enrollment” screening time:(from biostockclub)
https://neurosciencenews.com/artificial-intelligence-alzheimers-13097/

“The Future of Drug Trials Is Better Data and Continuous Monitoring” (from kevli33)
https://hbr.org/2019/05/the-future-of-drug-trials-is-better-data-and-continuous-monitoring

Alzheimer’s Disease conference, held October 24–27 2018 in Barcelona, Spain,
Which Are the Right Tests to Satisfy New FDA Guidance?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145129244

Changing FDA perspective toward trials and electronic data collection.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149099899

How RWE data will be used and new systems will be applied. (from nidan7500)
https://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RealWorldEvidence/UCM627769.pdf

Precedents and legal pathways to approval from Biostockclub & Nidan:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205166

New FDA accelerated approval guidance for labeling - from Nidan7500
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM390058.pdf

FDA planning new guidance, hires in cell and gene therapies for 2019 (From basparks79)
https://www.fiercebiotech.com/biotech/fda-planning-new-guidance-hires-cell-and-gene-therapies-for-2019

Link from the above post naming precedents for drug approval without a Random Controlled Trial:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932294/#!po=95.1923

New Rare Disease Draft Guidance (Feb. 2019 from nidan7500)
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM629579.pdf?rel=0

Electronic Health Records to be used in FDA trials (from Rubyred77)
https://ehrintelligence.com/news/ehr-data-to-provide-real-world-evidence-for-clinical-trials

New guidance for early stage Alzheimer's being developed in the U.S.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205259
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145208035

What is a Special Protocol Assessment?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140087471

Check this out on retrospective validation: (from Nidan7500)
https://www.nature.com/articles/6500363#hypothetical-safety-example-seeking-drug-approval-in-the-dnasubgroup-of-patients-with-less-risk-of-a-cardiovascular-adverse-events-after-trial-completion

4/3/19 - New position paper from FDA on AI supports Cognision partnership
(see Anavex Partners link at bottom of post for more on Cognision)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147990271

A 1995 paper predicts loss of U.S. credibility in drug approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145668454

Alzheimer's research receives largest ever funding boost in 2019 budget
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143880556

Are blinded, placebo trials really necessary?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147253537

Is corporate dominance of the FDA achieved by the User Fee Act (PDUFA)?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147227616
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147231843
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147234966

New programs to promote drug manufacturing innovation anounced by Gottleib(from Kevli33)
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm631293.htm?utm_campaign=021319_Statement_FDA%20announces%20programs%20to%20promote%20adoption%20of%20innovations%20in%20drug%20manufacturing&utm_medium=email&utm_source=Eloqua

Woodcock says the clinical trial system is broken. (From nidan7500)
https://www.biopharmadive.com/news/fdas-woodcock-the-clinical-trial-system-is-broken/542698/

Did the FDA cause the opioid crisis (from tradeherpete)
https://www.cbsnews.com/news/opioid-epidemic-did-the-fda-ignite-the-crisis-60-minutes/?ftag=MSF0951a18

On ACTC participation in the U.S.:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144487503
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145208260

Why ACTC is the holdup in North American Alzheimer's trials:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145449081

Update on NIH/ACTC (from Talon38)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147089795

Anavex, ACTC and Paul Aisen:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147089981

The pace of NIH-ACTC movement is Glacial. (from Nidan7500)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147091783

CDER expediting drugs - post from 04/08/19
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148080157

Payers and Right to Try:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148132893



In Peace, In War
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist